Tinea

Disclaimer: This information is for educational and informational purposes only and does not constitute medical advice. It is essential for clinicians to exercise independent medical judgment, consider individual patient circumstances, and consult the most current clinical guidelines and primary literature. Always prioritize patient safety and tailor treatment plans based on a comprehensive assessment.

Overview

• Definition: Tinea refers to a group of superficial fungal infections of the skin, hair, or nails caused by dermatophytes. These fungi are keratinophilic, meaning they infect keratinized tissues. The specific clinical presentation is often named after the affected body part (e.g., tinea pedis for feet).
• Epidemiology: Tinea infections are among the most common human fungal infections globally, affecting millions annually.
  • Prevalence: Varies geographically, but high incidence in warm, humid climates.
  • Tinea Pedis (Athlete's Foot): Extremely common, especially in adults; prevalence rates up to 15-20% in the general population. Higher in athletes, military personnel, and individuals using communal showers.
  • Tinea Cruris (Jock Itch): More common in adult males, particularly in warm weather or with tight clothing.
  • Tinea Corporis (Ringworm of the Body): Common in all age groups, often spread through direct contact with infected humans, animals, or fomites.
  • Tinea Capitis (Ringworm of the Scalp): Primarily affects prepubertal children (6-10 years old), more common in African-American children, often epidemic in schools. Less common in adults but can occur, especially in immunocompromised individuals.
  • Tinea Unguium (Onychomycosis): Very common, especially in adults >60 years; prevalence increases with age, affecting up to 10-20% of the adult population. Risk factors include tinea pedis, diabetes, peripheral vascular disease, and immunosuppression.
• Classification: Tinea infections are classified based on the anatomical site involved and the causative dermatophyte genus (e.g., Trichophyton, Microsporum, Epidermophyton).
  • Tinea Capitis: Scalp and hair.
  • Tinea Corporis: Body (non-hairy, non-groin, non-foot/hand).
  • Tinea Cruris: Groin, perineum, and inner thighs.
  • Tinea Pedis: Feet.
  • Tinea Manuum: Hands.
  • Tinea Unguium (Onychomycosis): Nails.
  • Tinea Barbae: Beard and mustache area (males).
  • Tinea Faciei: Face (non-beard area).
  • Tinea Incognito: Modified presentation due to inappropriate corticosteroid use.
  • Majocchi's Granuloma: Deep dermal or subcutaneous follicular infection, typically from Trichophyton rubrum.

Pathophysiology

• Mechanism: Dermatophytes are a group of fungi that have the unique ability to digest keratin using keratinase enzymes.
  1. Inoculation: Spores (arthroconidia) or hyphal fragments from an infected individual, animal, or environment come into contact with susceptible skin, hair, or nails.
  2. Adhesion and Germination: The fungi adhere to the stratum corneum and germinate, forming hyphae.
  3. Invasion: Hyphae invade the superficial keratinized layers. In hair, they can be endothrix (inside the hair shaft) or ectothrix (outside the hair shaft). In nails, they invade the nail plate, often starting distally and laterally (distal subungual onychomycosis).
  4. Growth and Inflammation: The fungi grow radially, consuming keratin. The host immune response to fungal antigens and metabolic products leads to inflammation, resulting in the characteristic annular lesions (ringworm). Pruritus is often caused by inflammation and irritation.
  5. Spread: Infections can spread peripherally, leading to central clearing as the fungus moves outward, or by autoinoculation to other body sites.
• Risk Factors:
  • Warm, Humid Environments: Perspiration and moisture create an ideal environment for fungal growth (e.g., tropical climates, occlusive clothing/footwear).
  • Communal Areas: Public showers, locker rooms, swimming pools (especially for tinea pedis and cruris).
  • Occlusive Footwear/Clothing: Traps moisture and heat.
  • Hyperhidrosis: Excessive sweating.
  • Minor Skin Trauma: Abrasions, cuts, maceration provide entry points for fungi.
  • Immunosuppression: HIV/AIDS, organ transplant recipients, chemotherapy, systemic corticosteroid use (can lead to more widespread or atypical infections, e.g., tinea incognito, Majocchi's granuloma).
  • Diabetes Mellitus: Impaired immunity, neuropathy, and angiopathy increase susceptibility.
  • Obesity: Skin folds create warm, moist environments.
  • Contact with Infected Individuals or Animals: Direct contact, sharing personal items (towels, combs).
  • Genetics: Possible predisposition in some individuals (e.g., chronic tinea pedis).
  • Specific Activities: Athletes (especially wrestlers – tinea gladiatorum), military personnel.
• Protective Factors:
  • Good Hygiene: Regular washing and drying of skin.
  • Keeping Skin Dry: Especially intertriginous areas, feet after bathing.
  • Wearing Breathable Fabrics and Footwear: Cotton socks, open-toed shoes when appropriate.
  • Avoiding Sharing Personal Items: Towels, combs, hats, shoes.
  • Protective Footwear: Wearing sandals or flip-flops in communal showers and locker rooms.
  • Prompt Treatment of Existing Infections: Prevents spread and recurrence.

Clinical Presentation

Signs and Symptoms

• Cardinal Features:
  • Pruritus: Itching, often the most bothersome symptom.
  • Erythematous, Scaly Lesions: Redness and flaking are characteristic.
  • Annular (Ring-shaped) Configuration with Central Clearing: Classic "ringworm" appearance, particularly in tinea corporis, cruris, and faciei. The active border is usually raised and erythematous, with vesicles or pustules.
• Early Signs:
  • Small, red papule or patch.
  • Mild pruritus.
  • Slight scaling.
  • May mimic insect bites or mild irritation.
• Advanced Signs:
  • Extensive Involvement: Larger lesions, multiple lesions, or involvement of significant body surface area.
  • Exacerbated Inflammation: Vesicles, bullae, pustules (e.g., bullous tinea pedis, highly inflammatory tinea corporis).
  • Lichenification: Thickening of the skin due to chronic scratching.
  • Tinea Capitis: Patchy alopecia (hair loss), erythema, scaling, pustules, black dots (broken hairs), kerion (boggy, painful inflammatory mass with follicular pustules, potentially leading to scarring alopecia).
  • Tinea Pedis (Chronic): Moccasin distribution (diffuse scaling, erythema, and hyperkeratosis of soles and sides of feet), possibly involving hands (two feet-one hand syndrome).
  • Tinea Unguium: Nail discoloration (white, yellow, brown, black), subungual hyperkeratosis (thickening under the nail), onycholysis (separation of nail from bed), nail plate dystrophy (crumbled, brittle).
• Atypical Presentations:
  • Tinea Incognito: Atypical appearance due to topical corticosteroid application. Lesions become less erythematous, less scaly, less defined, and more extensive, often losing their characteristic annular shape and becoming more diffuse and pustular. Diagnosis can be delayed.
  • Majocchi's Granuloma: Deep folliculitis caused by dermatophytes, often seen in immunocompromised individuals, those with extensive shaving, or after topical steroid use. Presents as red, firm papules or nodules along hair follicles, potentially with pustules or abscesses.
  • Id Reaction (Dermatophytid): An immunological reaction to a fungal infection elsewhere on the body, presenting as sterile, eczematous, or vesicular lesions (often on hands/feet) distant from the primary infection. Resolves with treatment of the primary fungal infection.

Physical Examination

• Inspection:
  • Tinea Corporis/Cruris/Faciei: Annular lesions with an active, raised, erythematous, often vesicular or pustular border and central clearing. Borders may be sharply demarcated.
  • Tinea Pedis:
    • Interdigital: Maceration, scaling, fissures, erythema between toes, particularly 4th and 5th.
    • Moccasin: Diffuse fine scaling, erythema, and mild hyperkeratosis of the sole and heel, often unilateral or asymmetrical.
    • Vesiculobullous: Vesicles or bullae on the sole or instep, often with surrounding erythema.
  • Tinea Capitis: Localized or diffuse patches of alopecia, scaling, erythema, broken hairs (black dots), pustules, possible lymphadenopathy (cervical, occipital). Kerion formation (boggy, painful mass) indicates severe inflammation.
  • Tinea Unguium: Nail plate thickening, discoloration (yellow, brown, white), crumbling, subungual debris, onycholysis. Multiple nails often involved.
  • Tinea Manuum: Unilateral fine scaling and hyperkeratosis of the palm, often accompanied by tinea pedis (one hand, two feet syndrome).
• Palpation:
  • Tenderness: May be present, especially with inflammatory forms (kerion, bullous tinea).
  • Induration: Thickening of the skin, especially in chronic forms (moccasin tinea pedis, tinea manuum).
  • Boggy sensation: Characteristic of kerion due to deep inflammation and pus.
• Special Tests:
  • Wood's Lamp Examination: Not routinely used for all dermatophyte infections as most common species (e.g., Trichophyton rubrum) do not fluoresce. However, some Microsporum species (e.g., M. canis, M. audouinii) causing tinea capitis may produce a characteristic green-yellow fluorescence of infected hairs. This can be useful for screening in endemic areas or confirming infection in suspected cases of Microsporum capitis.
  • Potassium Hydroxide (KOH) Microscopy: The most rapid and commonly used diagnostic test. Scraped scales, hair, or nail clippings are placed on a slide with 10-20% KOH solution (sometimes with dimethyl sulfoxide for faster dissolution of keratin). KOH dissolves keratinocytes, making fungal elements (hyphae, spores) visible.
    • Positive Finding: Presence of septate hyphae (branching filamentous structures) and/or arthrospores (chains of fungal spores).
    • Hair: Ectothrix (spores outside hair shaft) or Endothrix (spores inside hair shaft).
    • Nails: Mycelial elements and spores within or on the nail plate.

Diagnostic Approach

History Taking

• Key Questions:
  • Onset and Duration: When did the rash start? How long has it been present?
  • Symptoms: Pruritus (severity, timing), pain, burning, tenderness.
  • Appearance and Evolution: How has the rash changed over time? Has it spread?
  • Previous Treatments: What has been applied to the rash (especially topical steroids)? Did it improve or worsen? This is crucial for suspecting tinea incognito.
  • Exposure History:
    • Contact with other people with similar rashes (family, friends)?
    • Contact with pets (cats, dogs, guinea pigs, rabbits)?
    • Participation in contact sports (wrestling)?
    • Use of communal facilities (showers, locker rooms, gyms)?
    • Travel history.
  • Environmental Factors: Hot, humid climate; occlusive clothing/footwear; excessive sweating.
  • Review of Systems: Any systemic symptoms (rare for uncomplicated tinea), fever, malaise? (Suggests severe inflammation or secondary infection).
  • Medical History: Diabetes, immunosuppression (HIV, transplant, chemotherapy), other chronic conditions.
  • Medications: Especially immunosuppressants, systemic steroids.
  • Occupation/Hobbies: Any that involve prolonged moisture or exposure.
• Red Flags:
  • Extensive or Widespread Rash: Suggests immunocompromise or difficulty controlling infection.
  • Deep-seated Nodules or Abscesses: May indicate Majocchi's granuloma.
  • Severe Inflammation or Pain: Can indicate secondary bacterial infection, bullous tinea, or kerion.
  • Systemic Symptoms (Fever, Malaise): Rare with uncomplicated tinea, warrants investigation for secondary infection or other diagnoses.
  • Failure to Respond to Standard Therapy: Suggests incorrect diagnosis, resistance, or underlying immunocompromise.

Laboratory Tests

• First-Line:
  • Potassium Hydroxide (KOH) Microscopy:
    • Specimen Collection:
      • Skin: Scrape scales from the active border of the lesion with a No. 15 scalpel blade onto a glass slide.
      • Hair: Pluck affected hairs (if possible, with root) or scrape scales/debris from scalp with a blade or toothbrush for microsporum.
      • Nails: Scrape subungual debris from the most proximal and deepest part of the affected nail using a scalpel blade or curette. Ensure enough material is collected.
    • Procedure: Add a drop of 10-20% KOH solution (with or without DMSO) and a coverslip. Gently heat (do not boil) to aid dissolution. Examine under microscope at 10x and 40x.
    • Interpretation: Positive if septate hyphae and/or arthrospores are seen.
• Confirmatory:
  • Fungal Culture:
    • Purpose: Gold standard for species identification. Essential when:
      • KOH is negative but clinical suspicion remains high.
      • Infection is chronic, extensive, or refractory to treatment.
      • Systemic antifungal therapy is being considered (helps guide choice, especially if resistance is suspected).
      • Tinea capitis (to identify species and guide treatment duration).
      • Nail infection (onychomycosis) before initiating prolonged systemic therapy.
    • Media: Sabouraud Dextrose Agar (SDA) with cycloheximide and chloramphenicol (inhibits saprophytic fungi and bacteria).
    • Results: Growth typically takes 1-4 weeks. Species identification helps differentiate from non-dermatophyte molds or yeast infections.
  • Dermatophyte Test Medium (DTM): A rapid screening culture medium that changes color from yellow to red as dermatophytes grow. Not as reliable as standard culture for identification.
  • Nail Biopsy (with PAS staining):
    • Purpose: Often preferred for diagnosing onychomycosis, especially when KOH and fungal cultures are negative or equivocal. Provides higher sensitivity than KOH or culture alone.
    • Procedure: A small piece of the nail plate and nail bed is biopsied.
    • Interpretation: Periodic Acid-Schiff (PAS) stain highlights fungal elements.
  • PCR (Polymerase Chain Reaction):
    • Purpose: Rapidly detects dermatophyte DNA. Highly sensitive and specific.
    • Availability: Not widely available in all clinical settings, more common in specialized labs.
    • Advantage: Can identify species more quickly than culture.
• Monitoring:
  • Clinical Examination: Primary method for monitoring treatment response.
  • Liver Function Tests (LFTs): Recommended at baseline and periodically (e.g., monthly for the first 1-2 months, then as clinically indicated) for patients on oral antifungals like terbinafine or itraconazole, especially those with pre-existing liver conditions or prolonged therapy.
  • Complete Blood Count (CBC): Rarely indicated unless concerned about adverse effects (e.g., agranulocytosis with griseofulvin, very rare).
  • Renal Function Tests: Not routinely needed for most antifungals unless underlying renal impairment or specific drug (e.g., fluconazole dose adjustment needed for severe renal impairment).

Imaging

• Recommended: No routine imaging studies are recommended for the diagnosis of tinea.
• Advanced: In rare, complicated cases like suspected osteomyelitis secondary to severe onychomycosis in diabetic patients, or extensive deep soft tissue infection (Majocchi's granuloma with abscess formation), imaging such as MRI or CT may be considered to assess the extent of soft tissue involvement or bone infection. This is not for routine tinea diagnosis.

Management

Acute Management

Uncomplicated tinea is rarely an acute emergency. Management focuses on prompt initiation of antifungal therapy to relieve symptoms and prevent spread. - Immediate: * Symptomatic Relief: Antihistamines (e.g., diphenhydramine 25-50 mg PO PRN or hydroxyzine 10-25 mg PO PRN) for severe pruritus. * Wound Care (if applicable): For bullous lesions or maceration, consider warm water soaks, Burrow's solution (aluminum acetate) compresses for acute inflammation and drying. * Educate Patient: On hygiene measures to prevent spread (see Prevention section). - Stabilization: Not applicable as tinea is not a life-threatening condition. - Emergency: * Secondary Bacterial Infection: If signs of significant secondary bacterial infection (e.g., purulent drainage, increasing pain, fever, cellulitis), consider empiric antibiotics (e.g., cephalexin 500 mg PO QID or clindamycin 300 mg PO TID if MRSA suspected) in addition to antifungal therapy. * Kerion: While not an emergency, highly inflammatory kerion can lead to permanent scarring alopecia. Early aggressive oral antifungal treatment is critical, sometimes with a short course of oral corticosteroids (e.g., prednisone 0.5-1 mg/kg/day for 1-2 weeks, tapered) to reduce inflammation and scarring.

Chronic Management

Management varies significantly based on the type of tinea, extent, and patient factors.

Pharmacological

Topical Antifungals: First-line for most uncomplicated tinea corporis, cruris, pedis, and manuum. Applied once or twice daily for 2-4 weeks. Continue for at least 1 week after clinical clearance to prevent recurrence. * Azoles: Inhibit ergosterol synthesis. Generally fungistatic. * Clotrimazole 1% cream: BID (twice daily) for 2-4 weeks. * Miconazole 2% cream: BID for 2-4 weeks. * Ketoconazole 2% cream: Daily for 2-4 weeks. * Econazole 1% cream: Daily for 2-4 weeks. * Sertaconazole 2% cream: BID for 2-4 weeks. * Allylamines: Inhibit squalene epoxidase, leading to ergosterol deficiency and squalene accumulation (toxic). Generally fungicidal. * Terbinafine 1% cream/gel: Once daily for 1-2 weeks (more rapid clinical and mycological cure for tinea pedis, cruris, corporis). * Naftifine 1% cream/gel: Once daily for 2-4 weeks. * Butenafine 1% cream: Once daily for 2-4 weeks (or BID for 1 week for tinea pedis). * Other Topicals: * Ciclopirox 0.77% cream/gel: BID for 2-4 weeks. * Tolnaftate 1% cream/solution: BID for 2-4 weeks.

Oral Antifungals: Indicated for: * Tinea capitis (always) * Tinea unguium (onychomycosis) (always) * Extensive, widespread, or severe tinea corporis/cruris/pedis/manuum. * Tinea barbae. * Inflammatory tinea (e.g., kerion). * Immunocompromised patients. * Failure of topical therapy.

• Terbinafine: Fungicidal. Excellent for Trichophyton species.
  • Dosage: 250 mg PO daily.
  • Duration:
    • Tinea Capitis: 6-12 weeks (longer for T. tonsurans).
    • Tinea Corporis/Cruris/Pedis (severe): 2-4 weeks.
    • Onychomycosis: Fingernails: 6 weeks; Toenails: 12 weeks.
  • Adverse Effects: GI upset, headache, rash, taste disturbance, hepatotoxicity (rare, monitor LFTs).
• Itraconazole: Broad spectrum, fungistatic.
  • Dosage:
    • Continuous: 100-200 mg PO daily.
    • Pulse Dosing (Onychomycosis): 200 mg PO BID for 1 week/month. Fingernails: 2 pulses; Toenails: 3-4 pulses.
  • Duration: Varies.
  • Adverse Effects: GI upset, headache, rash, elevated LFTs, congestive heart failure (monitor, avoid in patients with ventricular dysfunction), drug interactions (CYP3A4 inhibitor).
• Fluconazole: Fungistatic.
  • Dosage: 150-200 mg PO weekly.
  • Duration:
    • Tinea Corporis/Cruris/Pedis: 2-4 weeks.
    • Tinea Capitis: 6 mg/kg PO weekly for 6-12 weeks (off-label for T. tonsurans, less effective than griseofulvin/terbinafine).
    • Onychomycosis: 150-450 mg PO weekly for 3-6 months (fingernails) or 6-12 months (toenails). Less effective than terbinafine or itraconazole for onychomycosis.
  • Adverse Effects: GI upset, headache, elevated LFTs, QT prolongation (rare).
• Griseofulvin: Fungistatic. Primarily for hair and nail infections. Older agent, still preferred for tinea capitis in children, especially due to excellent safety profile and appropriate dosing forms.
  • Dosage:
    • Microsize: 10-20 mg/kg/day PO (max 1g/day).
    • Ultramicrosize: 5-15 mg/kg/day PO (max 750mg/day). Take with fatty meal for absorption.
  • Duration:
    • Tinea Capitis: 6-12 weeks (or until culture negative/clinical cure).
    • Onychomycosis: Fingernails: 4-6 months; Toenails: 6-12 months.
  • Adverse Effects: GI upset, headache, rash, photosensitivity, elevated LFTs, leukopenia (rare, monitor CBC for prolonged use). Contraindicated in pregnancy.

Non-pharmacological

• Hygiene: Wash affected areas daily with soap and water.
• Drying: Thoroughly dry skin, especially intertriginous areas (groin, between toes, skin folds) after bathing. Use a separate towel for affected areas or use disposable paper towels.
• Powders: Antifungal powders (e.g., miconazole, tolnaftate) can help keep areas dry and prevent recurrence, especially for tinea pedis/cruris.
• Footwear: Wear breathable shoes (leather, mesh) and cotton socks. Change socks daily, or more frequently if sweaty. Alternate shoes to allow them to dry. Avoid occlusive footwear.
• Clothing: Wear loose-fitting, breathable clothing (e.g., cotton underwear) for tinea cruris.
• Avoid Sharing: Do not share towels, clothing, shoes, combs, or hats.
• Disinfection: Clean showers, floors, and contaminated objects. Wash contaminated clothes/bedding in hot water.

Monitoring

• Clinical Response: Assess improvement in symptoms (pruritus, scaling, erythema) and lesion size/appearance.
• Adverse Effects of Oral Antifungals:
  • LFTs: Monitor for hepatotoxicity with terbinafine, itraconazole, fluconazole. Baseline and at 4-6 weeks, then as clinically indicated. Discontinue if transaminases are >3x upper limit of normal or if symptoms of liver injury develop.
  • Drug Interactions: Be vigilant for interactions, especially with itraconazole (CYP3A4 inhibitor) and fluconazole.
  • CBC: For long-term griseofulvin use.
• Treatment Duration: Ensure patient completes the full course of therapy, even if symptoms improve earlier, to prevent recurrence.

Treatment Algorithms

• First-Line:

  • Localized, Non-Hair-Bearing Skin (Tinea Corporis, Cruris, Pedis, Manuum):
    • Topical Antifungal Cream: Allylamine (terbinafine 1% cream daily for 1-2 weeks) or Azole (clotrimazole 1% BID for 2-4 weeks). Allylamines generally provide faster resolution.
  • Tinea Capitis:
    • Oral Antifungal:
      • Griseofulvin: 10-20 mg/kg/day (microsize) or 5-15 mg/kg/day (ultramicrosize) daily for 6-12 weeks. (Preferred for children due to long track record of safety and effectiveness against Microsporum and Trichophyton).
      • Terbinafine: 250 mg PO daily for 2-4 weeks (effective for T. tonsurans, less for Microsporum). Dosing based on weight for children: <25 kg: 62.5 mg/day; 25-35 kg: 125 mg/day; >35 kg: 250 mg/day.
    • Adjunctive Therapy: Antifungal shampoo (selenium sulfide 2.5% or ketoconazole 2%) 2-3 times/week for 2-4 weeks to reduce spore shedding and prevent spread, especially in households.
  • Tinea Unguium (Onychomycosis):
    • Oral Antifungal: (Topicals generally ineffective alone due to poor penetration).
      • Terbinafine: 250 mg PO daily for 6 weeks (fingernails) or 12 weeks (toenails).
      • Itraconazole: Pulse dosing (200 mg PO BID for 1 week/month, 2 pulses for fingernails, 3-4 pulses for toenails).
    • Adjunctive Therapy: Nail debridement, topical agents (efinaconazole, tavaborole, ciclopirox lacquer) can be used as adjuncts in mild-moderate cases or when oral antifungals are contraindicated.
  • Tinea Barbae:
    • Oral Antifungal: Terbinafine 250 mg PO daily for 2-4 weeks, or Griseofulvin 10 mg/kg/day for 4-8 weeks.

• Second-Line:

  • Localized Tinea (if topical failure or extensive): Switch to oral antifungal as per specific tinea type guidelines.
  • Oral Antifungal Failure:
    • Re-evaluate diagnosis with fungal culture to confirm dermatophyte and identify species.
    • Check patient compliance.
    • Consider alternative oral antifungal agent.
    • Consider higher doses or longer durations (off-label, use expert consultation).
    • Rule out drug interactions impacting antifungal levels.
    • Assess for underlying immunocompromise.

• Refractory Cases:

  • Confirm Diagnosis: Perform repeat KOH and fungal culture (ideally with antifungal susceptibility testing, if available, though rarely indicated for dermatophytes).
  • Rule Out Tinea Incognito: Ask specifically about steroid use. Discontinue steroids immediately and treat appropriately.
  • Consider Combination Therapy: Sometimes a combination of oral and topical antifungals is used, especially for onychomycosis or extensive skin disease.
  • Majocchi's Granuloma: Requires systemic antifungal therapy, often prolonged (e.g., terbinafine 250 mg PO daily for 4-8 weeks or longer), possibly with surgical drainage if abscessed.
  • Immunocompromised Patients: May require higher doses or longer durations of systemic therapy. Prophylaxis may be considered in severe cases.
  • Referral: Consider referral to a dermatologist for complex, refractory, or atypical presentations.

Complications

• Common:
  • Post-inflammatory Hyperpigmentation/Hypopigmentation: Temporary discoloration of the skin after inflammation resolves.
  • Secondary Bacterial Infection: Impetiginization (crusting, pustules), cellulitis, erysipelas due to scratching or compromised skin barrier, especially with maceration (e.g., interdigital tinea pedis).
  • Eczematization: Development of eczematous changes due to chronic irritation and scratching.
  • Recurrence: Frequent, especially if risk factors are not addressed or if treatment is not completed.
• Serious:
  • Majocchi's Granuloma: Deep, invasive infection that can lead to scarring.
  • Kerion: Severe inflammatory reaction in tinea capitis, causing boggy, painful lesions and potentially permanent scarring alopecia.
  • Onycholysis and Nail Dystrophy: Can be disfiguring and impact quality of life; rarely severe enough to cause functional impairment.
  • Id Reaction (Dermatophytid): While not directly damaging, can be uncomfortable and cause diagnostic confusion.
• Long-term:
  • Chronic Nail Dystrophy: If onychomycosis is left untreated or recurs.
  • Scarring Alopecia: From severe tinea capitis (kerion).
  • Social and Psychological Impact: Chronic, visible skin conditions can lead to self-consciousness, embarrassment, and reduced quality of life.

Prognosis

• Factors:
  • Type of Tinea: Superficial infections (corporis, cruris) generally have an excellent prognosis with topical therapy. Hair and nail infections (capitis, unguium) require prolonged systemic therapy and have a longer treatment course with higher recurrence rates for onychomycosis.
  • Causative Organism: Some species are more difficult to eradicate (e.g., Trichophyton rubrum in nails, or Microsporum audouinii in scalp).
  • Host Immunity: Immunocompromised individuals (HIV, diabetes, transplant recipients) are more prone to widespread, severe, and recurrent infections, leading to a poorer prognosis for complete eradication.
  • Compliance: Adherence to medication regimens (especially for oral antifungals) and preventive measures significantly impacts outcome.
  • Timeliness of Diagnosis and Treatment: Early intervention prevents spread and complications.
  • Associated Comorbidities: Diabetes, peripheral vascular disease can complicate tinea pedis/unguium.
• Survival: Tinea infections are not directly life-threatening. Mortality is not a factor unless severe secondary bacterial infection leads to sepsis (extremely rare).
• Quality of Life: Can be significantly impacted by chronic pruritus, visible lesions, nail dystrophy, and social stigma. Successful treatment greatly improves quality of life. Recurrence can be frustrating and negatively impact QoL.

Prevention

• Primary: Preventing initial occurrence.
  • Good Personal Hygiene: Regular bathing, thorough drying of skin, especially intertriginous areas and feet.
  • Foot Care:
    • Wear clean, dry socks made of moisture-wicking materials (e.g., cotton, synthetics that wick sweat). Change socks daily or more often if wet.
    • Wear breathable footwear (leather, canvas, mesh) and alternate shoes to allow them to dry completely.
    • Wear sandals or flip-flops in communal areas (public showers, locker rooms, pools).
    • Apply antifungal powder to feet and inside shoes if prone to tinea pedis.
  • Clothing: Wear loose-fitting, breathable clothing, especially underwear for tinea cruris.
  • Avoid Sharing: Do not share personal items like towels, clothing, shoes, combs, brushes, or hats.
  • Pet Care: Treat infected pets (e.g., ringworm in cats/dogs) promptly, as they can be a source of human infection.
  • Awareness in Contact Sports: Implement hygiene protocols (showering after matches, cleaning mats) to prevent tinea gladiatorum.
• Secondary: Early detection and intervention.
  • Self-Monitoring: Educate patients about early signs of tinea so they can seek treatment promptly.
  • Screening: For athletes in contact sports, or children in schools during outbreaks of tinea capitis.
• Tertiary: Preventing complications and recurrence.
  • Complete Full Course of Treatment: Emphasize adherence, even after symptoms resolve.
  • Address Risk Factors: Counsel patients on managing hyperhidrosis, controlling diabetes, choosing appropriate footwear/clothing.
  • Prophylactic Measures: For individuals with chronic recurrent tinea pedis, regular use of antifungal powders or topical antifungal creams (e.g., once weekly for a few months) may reduce recurrences.

Special Populations

• Pediatric:
  • Tinea Capitis: Most common dermatophyte infection in children. Griseofulvin is typically the first-line oral treatment for tinea capitis due to its long history of safety, effectiveness against common pediatric pathogens (T. tonsurans, M. canis), and liquid formulations. Terbinafine is an alternative, particularly for T. tonsurans. Adjunctive antifungal shampoos (selenium sulfide or ketoconazole) are important to reduce spore shedding.
  • Tinea Corporis: Common in children, often from pets. Usually responds well to topical antifungals.
  • Onychomycosis: Less common than in adults but can occur. Oral antifungals are used, with weight-based dosing.
• Geriatric:
  • Tinea Unguium: Highly prevalent. Treatment can be challenging due to slower nail growth, comorbidities (diabetes, peripheral vascular disease), and polypharmacy (increased risk of drug interactions with oral antifungals). Longer treatment durations may be required.
  • Tinea Pedis/Cruris: May be more widespread or chronic due to reduced mobility, impaired immune function, or difficulty with personal hygiene.
  • Drug Interactions: Careful review of medications is crucial before prescribing oral antifungals, especially itraconazole.
  • Liver/Kidney Function: Assess baseline liver and kidney function before prescribing systemic antifungals and monitor closely.
• Pregnancy:
  • General Principle: Avoid systemic antifungals during pregnancy if possible. Topical antifungals are preferred for most tinea infections.
  • Topical Antifungals: Generally considered safe (e.g., azoles like clotrimazole, miconazole).
  • Oral Antifungals:
    • Griseofulvin: Category X. Absolutely contraindicated due to teratogenicity.
    • Fluconazole: Category D (especially high doses in first trimester). Avoid, particularly high doses or prolonged use.
    • Terbinafine: Category B. Considered safer than azoles in some sources, but still generally avoided in the first trimester. Use only if potential benefit outweighs risk.
    • Itraconazole: Category C. Avoid.
  • Management: If systemic treatment is unavoidable (e.g., severe tinea capitis/onychomycosis impacting quality of life or risk of spread), discuss risks/benefits with patient and consider referral to a high-risk OB or infectious disease specialist.
• Comorbidities:
  • Diabetes Mellitus: Patients are more susceptible to severe, chronic, and recurrent tinea (especially tinea pedis and onychomycosis) due to impaired immunity, poor circulation, and neuropathy. Aggressive treatment and strict control of blood glucose are essential. Increased risk of secondary bacterial infection (cellulitis, diabetic foot ulcers).
  • Immunosuppression (HIV, Organ Transplant, Systemic Steroids): Tinea can be more extensive, severe, atypical (e.g., Majocchi's granuloma), and difficult to eradicate. Systemic antifungal therapy is often required. Monitor for drug interactions (especially with calcineurin inhibitors in transplant patients). Prophylactic use of antifungals may be considered in some severe cases.
  • Peripheral Vascular Disease: Increased risk of tinea pedis/onychomycosis, and secondary bacterial infections that can lead to limb-threatening complications.

Clinical Pearls

• Diagnostic:
  • "If it's scaly, scrape it!": Always perform a KOH prep on any scaly rash suspected of being tinea. It's quick, inexpensive, and highly informative.
  • Tinea Incognito Alert: Always ask about topical corticosteroid use on the rash. If a rash worsened or changed presentation with steroids, suspect tinea incognito. These often have less classic borders and more diffuse erythema or pustules.
  • Culture for Oral Therapy: For tinea capitis and onychomycosis, a fungal culture is highly recommended before initiating prolonged oral antifungal therapy to confirm diagnosis, identify species, and guide treatment choice.
  • Nail Scraping Technique: For onychomycosis, scrape deeply from the most proximal and actively involved part of the nail plate, as the fungal burden is highest there. Debridement of hyperkeratotic material can improve specimen quality.
  • Look for "Two Feet-One Hand" Syndrome: Often unilateral tinea manuum accompanies bilateral tinea pedis, suggesting autoinoculation.
• Treatment:
  • Patient Education is Key: Emphasize compliance with the full course of treatment and adherence to preventive measures to minimize recurrence.
  • Topicals for Most Skin Tinea: Most tinea corporis, pedis, and cruris can be effectively treated with topical antifungals. Reserve oral agents for extensive, severe, inflammatory, hair/nail involvement, or failed topical therapy.
  • Oral Antifungals for Hair and Nails: Tinea capitis and onychomycosis almost always require systemic antifungal therapy due to the location of the infection.
  • Treat the Environment: For tinea pedis, advise patients to treat their shoes with antifungal sprays/powders and wash socks in hot water.
  • Kerion Management: For inflammatory tinea capitis (kerion), consider a short course of oral corticosteroids with oral antifungals to reduce inflammation and prevent scarring.
• Pitfalls:
  • Misdiagnosis: Confusing tinea with other scaly rashes like eczema, psoriasis, contact dermatitis, or candidiasis. A negative KOH does not completely rule out tinea; consider fungal culture if suspicion remains high.
  • Inappropriate Steroid Use: Applying topical corticosteroids to tinea can lead to tinea incognito, worsening the infection, masking the diagnosis, and delaying appropriate treatment.
  • Incomplete Treatment: Stopping antifungal medication prematurely once symptoms improve, leading to recurrence.
  • Missing Immunosuppression: Failing to recognize that widespread or recalcitrant tinea may be a sign of underlying immunosuppression (e.g., undiagnosed diabetes or HIV).
  • Ignoring Risk Factors: Not addressing predisposing factors (e.g., hyperhidrosis, occlusive footwear) leads to high rates of recurrence.
  • Over-reliance on Wood's Lamp: Remember that most common dermatophytes do not fluoresce. A negative Wood's lamp does not rule out tinea.

Recent Updates

• Guidelines: Current guidelines from organizations like the American Academy of Dermatology (AAD) and Infectious Diseases Society of America (IDSA) continue to emphasize KOH microscopy as the primary diagnostic tool and reinforce the role of oral antifungals for hair/nail infections.
• Evidence:
  • Ongoing research into shorter treatment durations and pulse regimens for onychomycosis with newer topical and oral agents.
  • Development of new topical agents with better nail penetration (e.g., efinaconazole, tavaborole for onychomycosis) offering more options for patients who cannot take oral medications or as adjunctive therapy.
  • Increasing awareness of antifungal resistance, though still uncommon for dermatophytes, prompting the need for culture and susceptibility testing in refractory cases.
• Controversies:
  • Optimal management of kerion (role and dosage of adjunctive steroids).
  • The role of prophylactic antifungal therapy in high-risk groups.
  • Management of asymptomatic onychomycosis, particularly in elderly or immunocompetent individuals (weighing treatment burden vs. benefit).

Key References

• Guidelines:
  • American Academy of Dermatology (AAD) Guidelines for the Management of Tinea Capitis.
  • Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the Diagnosis and Management of Fungal Infections.
• Studies:
  • Large-scale clinical trials on efficacy and safety of terbinafine, itraconazole, and fluconazole for tinea infections, particularly onychomycosis.
  • Studies comparing topical versus oral antifungal agents for various tinea types.
• Reviews:
  • Comprehensive reviews in major dermatology and infectious disease journals (e.g., Journal of the American Academy of Dermatology, Clinical Infectious Diseases).
  • Standard textbooks on dermatology and medical mycology (e.g., Bolognia, Fitzpatrick's Dermatology in General Medicine).